Phuturdex › Diseases › Testicular Neoplasms
Drugs in development · updated 30 October 2026
Testicular Neoplasms: drugs in development
As of 30 October 2026 there are 14 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for testicular Neoplasms. 8 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| 111In-TJD-31 | I | 1 | NCT07815951 |
| [68Ga]Ga-FAPI-46Gallium Ga 68 FAPi-46 | I | 1 | NCT04459273 |
| Claudin6 | I | 1 | NCT05410717 |
| CTIM-76 | I | 1 | NCT06515613 |
| GV20-0251 | I | 1 | NCT07106827 |
| Mesothelin | I | 1 | NCT05410717 |
| VeliparibABT-888 | I | 1 | NCT01366144 |
| XmAb541 | I | 1 | NCT06276491 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CisplatinCis Platinum, Cisplatine | III | 4 | NCT02341989 |
| CarboplatinCarboplatine, Paraplatin | III | 3 | NCT02341989 |
| MethadoneMethadose®, Westadone® | III | 1 | NCT06593665 |
| EtoposideAvopef®, Etopophos Preservative Free® | II | 2 | NCT07847190 |
| PaclitaxelTaxol, Paxlitaxel | II | 2 | NCT07847190 |
| BleomycinBleomicina, Blenoxane® | II | 1 | NCT07847190 |
| TarlatamabImdelltra®, Imdylltra® | I–II | 1 | NCT06814496 |
| BrodalumabSiliq®, Kyntheum® | I | 1 | NCT06673329 |
| Sodium Thiosulfatetiosulfate, Pedmark® | I | 1 | NCT07218913 |
Sorted by most advanced phase and number of active trials.
All 17 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Urachal cancer 8 drugs
- Parathyroid neoplasm 4 drugs
- Fibrolamellar hepatocellular carcinoma 22 drugs
- Hemangiosarcoma 58 drugs
- Anus neoplasm 28 drugs
- Carcinosarcoma 25 drugs
- Cholangiocarcinoma 136 drugs
- Adenoid cystic carcinoma 26 drugs
- Mesothelioma 54 drugs
- Neuroblastoma 95 drugs
- Adrenal gland neoplasm 10 drugs
- Penile neoplasm 26 drugs
Broader categories
- Urogenital Diseases 16 drugs
- Male urogenital disease 19 drugs
- Neoplasm 671 drugs
- Endocrine gland neoplasm 3 drugs
- Urogenital neoplasm 38 drugs
- Genital Diseases 7 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D013736 “Testicular Neoplasms”.